Tivozanib: First Global Approval.

Abstract

Tivozanib (Fotivda®) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. Tivozanib is at various stages of development in other countries for advanced RCC and advanced solid tumours. This article summarizes the milestones in the development of tivozanib leading to this first global approval in Europe for the treatment of adults with advanced RCC.

• Authors: Esther S Kim
• Journal: Drugs (Drugs) Vol. 77 Issue 17 Pg. 1917-1923 (Nov 2017) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 28971328 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Phenylurea Compounds
• Protein Kinase Inhibitors
• Quinolines
• tivozanib
• Receptors, Vascular Endothelial Growth Factor

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Renal Cell (drug therapy)
• Drug Approval
• Europe
• Humans
• Kidney Neoplasms (drug therapy)
• Molecular Targeted Therapy (methods)
• Phenylurea Compounds (therapeutic use)
• Protein Kinase Inhibitors (therapeutic use)
• Quinolines (therapeutic use)
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)